Tolvaptan special update: Accepted for priority review by FDA

A major announcement was made recently by Otsuka Pharmaceutical Co., Ltd. that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company’s new drug application (NDA) for the potential use of tolvaptan for the treatment of autosomal...

Special announcement about tolvaptan

A major announcement was made by Otsuka Pharmaceutical Co. on Saturday, Nov. 3, 2012, at the American Society of Nephrology (ASN) meeting regarding the results of the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes...